The Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors publication covers some of the latest practice-changing advances as it relates to novel treatment strategies for patients with BRAF-mutated solid tumors.
KIN-2787 Looks to Fill Unmet Need in Class II/III BRAF-Altered Solid Tumors
Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.
Dr. McKean on the Importance of Molecular Profiling in Metastatic Melanoma
Meredith McKean, MD, MPH, discusses the importance of molecular profiling in melanoma.
Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma
Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.
Investigation Into the Actionability of Atypical BRAF Mutations Continues in Solid Tumors
Developing BRAF inhibitors for patients with atypical class II and III mutations has become an exciting area of research.
Dr. Kato on the Characterization of BRAF Mutations in Oncology
Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.
Dr. Perez on the Potential Utility of KIN-2787 in BRAF-Mutated Solid Tumors
Cesar Augusto Perez, MD, discusses the potential utility of KIN-2787 in BRAF-mutated solid tumors.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.